Lineage Cell Therapeutics, Inc. (LCTX)

NYSEAMERICAN: LCTX · Real-Time Price · USD

1.810

+0.030 (1.69%)

At close: Feb 20, 2026, 4:00 PM EST

1.807

-0.003 (-0.17%)

After-hours: Feb 20, 2026, 8:00 PM EST

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	439	111	191	199	413	264
Market Cap Growth	227.08%	-41.93%	-4.09%	-51.84%	56.44%	98.01%
Enterprise Value	401	79	151	134	349	228
Last Close Price	1.81	0.50	1.09	1.17	2.45	1.76
PS Ratio	40.55	11.66	21.32	13.53	95.13	144.57
PB Ratio	18.92	1.44	3.08	2.77	4.54	2.78
P/TBV Ratio	-	5.23	30.84	12.45	11.89	6.86
P/FCF Ratio	-	-	-	307.85	-	-
P/OCF Ratio	-	-	-	187.79	-	-
EV/Sales Ratio	37.05	8.36	16.88	9.11	80.50	124.70
EV/FCF Ratio	-	-	-	207.31	-	-
Debt / Equity Ratio	0.13	0.03	0.05	0.05	0.03	0.04
Debt / FCF Ratio	-	-	-	6.03	-	-
Net Debt / Equity Ratio	-1.82	-0.59	-0.52	-0.75	-0.61	-0.40
Net Debt / EBITDA Ratio	1.92	2.17	1.59	2.48	1.15	1.55
Net Debt / FCF Ratio	1.81	1.91	1.11	-83.56	2.32	1.90
Asset Turnover	0.12	0.09	0.08	0.10	0.03	0.02
Quick Ratio	4.33	3.47	2.02	3.07	2.32	5.35
Current Ratio	4.50	3.65	2.14	3.16	2.37	5.66
Return on Equity (ROE)	-157.75%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%
Return on Assets (ROA)	-13.65%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%
Return on Capital Employed (ROCE)	-25.30%	-21.60%	-25.50%	-21.50%	-38.60%	-26.40%
Earnings Yield	-15.43%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%
FCF Yield	-4.76%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%
Buyback Yield / Dilution	-25.54%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q